{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-056469","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.817387+00:00","generated_at":"2026-06-28T13:54:20.156592+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Adial appoints former Indivior CFO Cary Claiborne to board of directors","bullets":["Cary J. Claiborne appointed to Adial's board, expanding board to seven members.","He previously served as CFO and board member of Indivior PLC, a specialty pharma company.","Received an option for 60,000 shares at $3.15, vesting monthly over 36 months.","CEO Stilley noted his experience will aid preparations for Phase 3 trial completion and potential commercial launch.","Claiborne's background includes CFO roles at Sucampo Pharmaceuticals and Osiris Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-056469","json":"https://secwatch.observer/filing/0001213900-21-056469.json","markdown":"https://secwatch.observer/filing/0001213900-21-056469.md","text":"https://secwatch.observer/filing/0001213900-21-056469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021056469/0001213900-21-056469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021056469/ea149870-8k_adialpharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:54:20.156592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a414da791","claim":"Cary J. Claiborne was appointed as director at ADIAL PHARMACEUTICALS, INC..","evidence_excerpt":"On November 2, 2021, Cary J. Claiborne joined the board of directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”) to serve as a Class I member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021056469/0001213900-21-056469-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}